Sep 29 2010
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.
These generic Riluzole Hydrochloride tablets contain Riluzole Hydrochloride 50 mg. Riluzole Hydrochloride tablets are indicated in the treatment of amyotrophic lateral sclerosis.
Rilutek has annual sale of approximately $ 50 million in the US.
Source:
: Sun Pharmaceutical Industries Ltd.